Fractyl Laboratories Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fractyl Laboratories Inc.
The first-in-human study of Fractyl's Revita duodenal mucosal resurfacing system shows significant short-term improvement in hyperglycemia in patients with type 2 diabetes, with few adverse events.
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
Surgical Equipment & Devices
- Minimally or Less Invasive